Repeat survey of minimal clinically important difference:
Between 24th January and 5th March 2020, 650 women completed our survey, of whom 450 (73%) had current or prior experience of ICP. 116 clinicians completed the survey. The demographics of each group can be found in Table S3.
Clinicians indicated that they considered that a 30 mm (median, IQR 20 to 30 mm) improvement in the visual analogue scale score (from a baseline score of 60 mm) would be a clinically important difference, as did the women with prior experience of ICP (median 30 mm, IQR 20 to 40 mm; Figure S4). Of women who responded to the survey, 9.6% (43/450) said that they would consider taking a drug every day for a 5 mm reduction in itch severity. Women’s responses did not differ depending on prior experience of ICP (median 30 mm, IQR 20 to 40 mm; Figure S5).
Clinicians estimated that a minimum of 35% (median, IQR 22.5% to 50%) of women would need to change from being unable to sleep through the night to being able to sleep through the night before they would consider prescribing UDCA. Women estimated that 50% (median, IQR 20% to 70%) of women would need to change status before they would consider taking the drug (Figure S6).